Difference between revisions of "Cancer drugs"
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
| notes? | | notes? | ||
|- | |- | ||
| | | gefitinib | ||
| Iressa | | Iressa | ||
| 3496 Euros/month<ref name=spiegel8_8_11_124/> | | 3496 Euros/month<ref name=spiegel8_8_11_124/> | ||
| [[Lung cancer]] | | [[Lung cancer]] | ||
| | | EGFR inhibitor - like erlotinib | ||
|- | |- | ||
| panitumumab | | panitumumab | ||
Revision as of 02:53, 15 August 2011
This article covers cancer drugs from a pathology perspective.
Drugs in a table
| Non-proprietary name | Trade name | Cost | Indication | Notes |
|---|---|---|---|---|
| cetuximab | Erbitux | 5267 Euros/month[1] | stomach cancer, head & neck cancer | notes? |
| trastuzumab | Herceptin | 3345 Euros/month[1] | breast cancer, stomach cancer | notes? |
| gefitinib | Iressa | 3496 Euros/month[1] | Lung cancer | EGFR inhibitor - like erlotinib |
| panitumumab | Vectibix | 3537 Euros/month[1] | indication | notes? |
| fulvestrant | Faslodex | 719 Euros/month[1] | breast cancer | selective estrogen receptor down-regulator (SERD) |
| letrozole | Femara | 4189 Euros/month[1] | indication | non-steroidal aromatase inhibitor |
| imatinib | Gleevec/Glivec | 4189 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
| non-proprietary name | Sprycel | 7513 Euros/month[1] | ALL, CML | notes? |
| nilotinib | Tasigna | 5685 Euros/month[1] | CML | tyrosine kinase inhibitor |
| lapatinib | Tyverb | 3441 Euros/month[1] | breast cancer | tyrosine kinase inhibitor / HER2 growth receptor pathway blockade |